Bank of America’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $31.7M | Buy |
1,230,957
+96,774
| +9% | +$1.99M | ﹤0.01% | 2084 |
|
|
2026
Q1 | $21.8M | Buy |
1,134,183
+202,039
| +22% | +$4.02M | ﹤0.01% | 2311 |
|
|
2025
Q4 | $15.4M | Sell |
932,144
-28,994
| -3% | -$489K | ﹤0.01% | 2512 |
|
|
2025
Q3 | $14M | Buy |
961,138
+310,916
| +48% | +$4.47M | ﹤0.01% | 2967 |
|
|
2025
Q2 | $9.1M | Buy |
650,222
+202,465
| +45% | +$2.85M | ﹤0.01% | 3315 |
|
|
2025
Q1 | $6.09M | Buy |
447,757
+177,424
| +66% | +$3.4M | ﹤0.01% | 3618 |
|
|
2024
Q4 | $5.51M | Sell |
270,333
-77,831
| -22% | -$1.99M | ﹤0.01% | 3496 |
|
|
2024
Q3 | $10.1M | Sell |
348,164
-393,884
| -53% | -$9.76M | ﹤0.01% | 3048 |
|
|
2024
Q2 | $17.2M | Sell |
742,048
-109,928
| -13% | -$2.11M | ﹤0.01% | 2396 |
|
|
2024
Q1 | $17.5M | Buy |
851,976
+393,338
| +86% | +$7.39M | ﹤0.01% | 2423 |
|
|
2023
Q4 | $9.84M | Buy |
458,638
+162,844
| +55% | +$3.23M | ﹤0.01% | 2911 |
|
|
2023
Q3 | $6.1M | Buy |
295,794
+25,549
| +9% | +$648K | ﹤0.01% | 3225 |
|
|
2023
Q2 | $7.97M | Sell |
270,245
-149,591
| -36% | -$4.21M | ﹤0.01% | 2939 |
|
|
2023
Q1 | $9.67M | Buy |
419,836
+85,064
| +25% | +$2.34M | ﹤0.01% | 2858 |
|
|
2022
Q4 | $9.31M | Buy |
334,772
+114,555
| +52% | +$3.41M | ﹤0.01% | 2758 |
|
|
2022
Q3 | $6.76M | Buy |
220,217
+101,150
| +85% | +$3.29M | ﹤0.01% | 3026 |
|
|
2022
Q2 | $3.5M | Sell |
119,067
-122,168
| -51% | -$3.2M | ﹤0.01% | 3766 |
|
|
2022
Q1 | $7.76M | Buy |
241,235
+112,287
| +87% | +$3.86M | ﹤0.01% | 3130 |
|
|
2021
Q4 | $5.75M | Buy |
128,948
+51,102
| +66% | +$2.42M | ﹤0.01% | 3520 |
|
|
2021
Q3 | $3.92M | Buy |
77,846
+14,094
| +22% | +$794K | ﹤0.01% | 3800 |
|
|
2021
Q2 | $5M | Buy |
63,752
+11,981
| +23% | +$741K | ﹤0.01% | 3501 |
|
|
2021
Q1 | $2.96M | Buy |
51,771
+4,477
| +9% | +$300K | ﹤0.01% | 3898 |
|
|
2020
Q4 | $3.96M | Buy |
47,294
+18,191
| +63% | +$1.1M | ﹤0.01% | 3345 |
|
|
2020
Q3 | $1.04M | Sell |
29,103
-4,307
| -13% | -$130K | ﹤0.01% | 4176 |
|
|
2020
Q2 | $809K | Buy |
33,410
+5,801
| +21% | +$136K | ﹤0.01% | 4274 |
|
|
2020
Q1 | $483K | Buy |
27,609
+2,565
| +10% | +$53.5K | ﹤0.01% | 4523 |
|
|
2019
Q4 | $436K | Sell |
25,044
-18,580
| -43% | -$309K | ﹤0.01% | 5104 |
|
|
2019
Q3 | $668K | Sell |
43,624
-37,040
| -46% | -$708K | ﹤0.01% | 4859 |
|
|
2019
Q2 | $1.68M | Sell |
80,664
-1,198
| -1% | -$26.8K | ﹤0.01% | 4172 |
|
|
2019
Q1 | $1.9M | Buy |
81,862
+64,495
| +371% | +$1.35M | ﹤0.01% | 4024 |
|
|
2018
Q4 | $359K | Buy |
17,367
+11,580
| +200% | +$210K | ﹤0.01% | 5146 |
|
|
2018
Q3 | $126K | Buy |
5,787
+1,563
| +37% | +$25.9K | ﹤0.01% | 5760 |
|
|
2018
Q2 | $64K | Buy |
4,224
+2,740
| +185% | +$51.6K | ﹤0.01% | 6008 |
|
|
2018
Q1 | $30K | Buy |
1,484
+1,200
| +423% | +$24.7K | ﹤0.01% | 6232 |
|
|
2017
Q4 | $4K | Buy |
+284
| New | +$5.1K | ﹤0.01% | 6759 |
|
Other funds holding DNLI
Bank of America's DNLI Position: Q2 2026 in Review
Bank of America increased its Denali Therapeutics (DNLI) stake by 8.5% in Q2 2026, buying an estimated $1.99M and bringing the position to 1,230,957 shares worth $31.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2084.
Bank of America first reported a position in DNLI in Q4 2017 and has held it in 35 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.
- Bank of America held 1,230,957 shares of Denali Therapeutics worth $31.7M as of Q2 2026.
- Bank of America bought 96,774 Denali Therapeutics shares in Q2 2026, an estimated $1.99M.
- Denali Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q2 2026, its #2084 holding.
- Bank of America first reported a position in Denali Therapeutics in Q4 2017 and has held it in 35 quarters since.
- 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.
Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.